Influence of short-term intervention of different doses Rosuvastatin on plasma levels of TM and hsCRP in ACS patients
10.3969/j.issn.1008-0074.2013.03
- VernacularTitle:不同剂量瑞舒伐他汀短期干预对ACS患者血浆TM、hsCRP水平的影响
- Author:
Yongcai SU
;
Xiaole ZHANG
;
Xinwu FENG
;
Liangxian SU
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Thrombomodulin;
C-reactive protein;
Rosuvastatin
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2013;22(3):256-260
- CountryChina
- Language:English
-
Abstract:
Objective: To explore influence of short-term intervention of different doses rosuvastatin on plasma levels of thrombomodulin (TM) and high sensitive C reactive protein (hsCRP) in patients with acute coronary syndrome (ACS). Methods: A total of 32 ACS patients were enrolled, randomly and equally divided into rosuvastatin 10mg group and rosuvastatin 20mg group, and another 16 patients without coronary heart disease were enrolled as normal control group. Enzyme linked immunosorbent assay (ELISA) was used to measure plasma levels of TM and hsCRP in two rosuvastatin groups before and after treatment and in normal control group at admission. Adverse drug reactions and incidence rates of cardiovascular events within one month were observed in two rosuvastatin groups. Results: Plasma levels of TM and hsCRP in two groups of ACS patients were both significantly higher than those of normal control group before treatment, P<0.001 all; compared with before treatment, there were significant decrease in levels of TM [10mg group：(54.09±52.45) μg/dl vs. (15.65±2.30) μg/dl，20mg group：(70.27±62.43) μg/dl vs. (19.86±5.49) μg/dl] and hsCRP [10mg group：(126.35±76.08) ng/ml vs. (54.85±45.30) ng/ml，20mg group：(125.35±60.29) ng/ml vs. (58.14±53.54) ng/ml] in two rosuvastatin groups after treatment 7d, P<0.01 all; But there were no significant differences in influences of two doses on plasma levels of TM and hsCRP in ACS patients, P＞0.05 all. There was no significant difference in incidence rate of adverse drug reactions between two rosuvastatin groups during follow-up (P>0.05); compared with rosuvastatin 10mg group, there was significant decrease in incidence rate of major adverse cardiovascular events（MACE）: Relapse angina pectoris (62.50% vs. 18.75%, P<0.01) in rosuvastatin 20mg group. Conclusions: Early intensive statins medication （rosuvastatin 20mg）can decrease plasma levels of thrombomodulin and high sensitive C reactive protein, and rosuvastatin 20mg/d can effectively decrease incidence rate of cardiovascular events without significant increase incidence rate of adverse drug reactions in ACS patients.
- Full text:P020130724837241116975.doc
